Viewing Study NCT03843658


Ignite Creation Date: 2025-12-25 @ 12:01 AM
Ignite Modification Date: 2026-02-25 @ 6:59 PM
Study NCT ID: NCT03843658
Status: UNKNOWN
Last Update Posted: 2019-02-18
First Post: 2019-02-14
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Identifying Novel Biomarkers in Early Rheumatology Patients
Sponsor: Arthritis Northwest PLLC
Organization:

Study Overview

Official Title: Identifying Novel Biomarkers in Early Rheumatology Patients
Status: UNKNOWN
Status Verified Date: 2019-02
Last Known Status: NOT_YET_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Patients new to a rheumatology practice will be asked if they want to consent to their blood sample, medical records, and hand/foot x-rays (with sharp scores) for the analysis and correlation with the diagnosis they will receive from the rheumatologist.
Detailed Description: At the end of their first visit new rheumatology patients will be asked for their interest in joining the Inova biomarker study. If yes, the patient will be consented, blood will be drawn for the Inova biomarkers, and x-rays will be sent for sharp scoring. Patients may decline and will not be part of the Inova study. Patients who decline will continue to receive standard of care treatment henceforth.

Patients in the Inova trial will receive a diagnosis from their doctor and are placed into separate cohorts based upon their diagnosis. The Inova biomarker results of each cohort will be cross-correlated with diagnoses, pre-screening tool results. Baseline disease activity and sharp scores will also be correlation variables.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: